Consumer Wearable Devices have the potential to influence the lives of millions, but maintaining the performance and accuracy of new sensor technologies can be a rough transition from component to product. Despite this abuse, users expect their smartwatch to keep working, years later, all while providing health insights. In this talk, we will cover some of the integration challenges unique to consumer electronics: size, power consumption, environmental reliability, and sensor performance expectations.

Patient involvement in their own health management has become a stronger demand, reinforced by the current pandemic period. Connected medical wearables are great candidates to monitor patient’s health remotely. At the heart of these devices: the sensors. Discover what are the current wearable and sensor market trends, emerging sensors and advanced technologies fostering adoption of connected medical devices in a growing patient-centric care vision.

This presentation will focus on our recent efforts for using microneedle sensor arrays for simultaneous, minimally invasive, real-time monitoring of multiple biomarkers. Owing to the arrayed nature of the microneedle structures, various target analytes can be detected at different individually addressable microneedles for realizing such multiplexed sensing operation. The preparation and characterization of such wearable electrochemical microneedle sensor arrays will be described, along with their current status, advantages, latest applications, and future prospects and challenges.

This talk presents a study of near-field radiometry for internal temperature measurements of the human body. Measurements are presented using a calibrated radiometer at 1.4GHz for various phantom tissues. It is shown that temperature can be tracked within a fraction of a degree for a phantom muscle tissue layer under phantom fat and skin layers

Wearable devices have tremendous potential for real-time monitoring and disease detection for the current COVID-19 global pandemic. We have developed a real-time alarming system to detect onset of COVID-19 prior to symptoms and are launching a large-scale study to enroll participants globally. Our study provides a roadmap for large-scale detection of respiratory viral infections in advance of symptoms.

The Early Notification to Act, Control, and Treat (ENACT) Program within the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services, partners with researchers to develop novel physiological and biomarker sensors and new data analytics strategies that can detect early health changes in an individual.

Aerosolized biological samples are difficult to collect and identify without the aid of large air samplers. Furthermore, since the discovery of infectious aerosolized SARS-CoV-2, there has been an increased need to automatically collect, process, and analyze aerosol samples for biosurveillance purposes. To address this need, we have developed an automated elution module that couples with a microwell aerosol collector to collect and elute aerosolized biological sample for downstream identification via PCR or LAMP.

During the pandemic we need accurate pulse oximetry at home as an assessment tool to gauge the severity of COVID-19 infection and identify patients at risk of poor outcomes. Methods: We performed in human hypoxia testing to determine if smartphone integrated biosensor/algorithm suites meet the FDA/ISO requirements for clinical pulse oximetry. Findings: The RMSD of over 257 data points based on blood sample analysis obtained from 12 human volunteers tested was 2.6% in the Samsung Galaxy S9.Interpretation: This is the first report of smartphone derived pulse oximetry that meets full FDA/ISO accuracy certification requirements. 

This presentation will describe the development of a medical grade, fully integrated, home-based patient care platform for cardiovascular monitoring of a patient in virtually any setting. The system collects and transmits patient cardiac measurements to LIVMOR cloud services, providing both the patient and patient-designated caregivers, physicians, and clinicians immediate access to securely protected patient health information, including medically valid measurements of Heart Rate, Heart Rate Variability (HRV) and Respiration Rate.

For millions of patients with heart disease, having a 12-lead ECG at home empowers them to manage their own disease under doctors' guidance. PCA 500 from QT Medical is the first medical grade 12-lead ECG cleared by the FDA for patient use at home. Not only did QT Medical develop the home ECG platform, they also developed the business model Xpress ECG, an online order mail delivery home ECG test. 

Dr. Bloom will detail how he and his co-founders were able to develop a viable business model centered around remote monitoring before that technology was commonly used in health care. Dr. Bloom will walk through what it took to get the company off the ground and the process behind designing a device suited to the population Podimetrics serves, one that successfully removes the burden from the patient and increases engagement.

The COVID-19 pandemic has disrupted the routines of many people who use continuous glucose monitoring sensors to help manage their diabetes. In this presentation, we will show how population-level metrics of glycemic control have evolved before and after stay-at-home orders and throughout the rest of 2020. Temporal, geographical and socio-economic differences provide further insights on the widespread impact of the pandemic.